Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol educational outreach for Excedrin Migraine targeted to serious headache sufferers.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL EDUCATIONAL OUTREACH FOR EXCEDRIN MIGRAINE will be directed at consumers who want to learn more about serious headaches that may be migraines. Bristol-Myers Squibb estimates that upwards of 25 mil. Americans, mostly women (75%) and those in their 30s, suffer from headaches that could be classified as migraines, and that an estimated 17 mil. of those headache sufferers do not seek professional treatment. FDA's estimates of migraine sufferers are slightly lower, at 16 mil. to 18 mil., nonetheless, a large potential customer base for Excedrin Migraine.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087959

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel